Year: 2025
Type: editorial
Abstract: CLL therapy.Promising combinations of various BTK and BCL2 inhibitors are likewise, under active investigation.Our next challenges will consist of better accounting for patient heterogeneity and higher resolution assessment of efficacy and safety.Refining objectives through novel end points and setting innovative designs, such as MRD-guided treatment duration and de-escalation protocols will be key to minimizing toxicity without compromising efficacy. Conflict-of-interest disclosure: R.G. reports receiving
Source: Blood
Authors: Mazyar Shadman, Ajay K. Gopal
Institutions: University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415704108